The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have been ...

Viking Therapeutics' new GLP-1 weight loss pill, VK2735, helped patients shed 12.2% of their body weight in 13 weeks. The pill is proving "safe and well-tolerated." However, one-fifth of participants ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have been ...

Viking Therapeutics' new GLP-1 weight loss pill, VK2735, helped patients shed 12.2% of their body weight in 13 weeks. The pill is proving "safe and well-tolerated." However, one-fifth of participants ...

Viking Therapeutics' new GLP-1 weight loss pill, VK2735, helped patients shed 12.2% of their body weight in 13 weeks. The pill is proving "safe and well-tolerated." However, one-fifth of participants ...

At $24 versus the $89 analyst average price target, Viking trades at a steep discount. While some targets will likely be revised lower, the size of the decline appears excessive for a company with no ...

Biotech companies (XBI) are starting to make a comeback of sorts, as XBI has even managed to outperform the broader healthcare peers (XLV) since the April lows. However, that shouldn't have been ...

Numerous companies in the healthcare sector are feverishly busy developing obesity drugs, as these products have taken the medical world by storm. One of the more prominent developers, clinical-stage ...

Viking Therapeutics presents a high-risk, high-reward opportunity in the exploding GLP-1 weight loss market, where early clinical data for its VK2735 drug shows competitive results against current ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...